News
GSK, Pfizer and CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 million plus royalties to ...
TipRanks on MSN16h
Pfizer’s Updated COVID-19 Vaccine Study: What Investors Need to KnowPfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Estimated Vaccine Effectiveness ...
In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
16hon MSN
Clinical trials have shown the mRNA vaccines for COVID-19 are safe and effective, especially at preventing severe illness, ...
Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...
Pfizer’s clinical trials in children 5 to 11 did not measure the vaccine’s effectiveness against COVID-19. Effectiveness was “never the intended primary endpoint,” Anderson said.
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results